Aamund: We have reached the pearly gates
Founder, major shareholder and former Chairman in Bavarian Nordic, Asger Aamund, calls it a “happy day”, although Wednesday’s licensing pact with J&J was expected. And he admits that it gives him a sense of satisfaction to see so many people be wrong about the Danish biotech company.
BY BENJAMIN WERNER CHRISTENSEN
With Wednesday’s multi-million-dollar deal with Janssen, a subsidiary to Johnson & Johnson, the Danish biotech company Bavarian Nordic begins a new era. MedWatch spoke to Asger Aamund, founder, major shareholder with about 7% and former Chairman of the Board in Bavarian Nordic, about his take on the situation.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
”You won’t hear from us until we have struck a deal”
For abonnenter
Does Bavarian have a blockbuster in the making?
For abonnenter
Bavarian looking for partnerships for cancer vaccine
For abonnenter
